<SEC-DOCUMENT>0000950170-24-053551.txt : 20240506
<SEC-HEADER>0000950170-24-053551.hdr.sgml : 20240506
<ACCEPTANCE-DATETIME>20240506161015
ACCESSION NUMBER:		0000950170-24-053551
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20240506
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240506
DATE AS OF CHANGE:		20240506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oric Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001796280
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				471787157
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39269
		FILM NUMBER:		24917574

	BUSINESS ADDRESS:	
		STREET 1:		240 E. GRAND AVE.
		STREET 2:		2ND FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 388-5600

	MAIL ADDRESS:	
		STREET 1:		240 E. GRAND AVE.
		STREET 2:		2ND FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>oric-20240506.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-05-06T13:07:09.4761+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:oric="http://www.oricpharma.com/20240506" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_92bdf68c-569c-4b31-86c2-b683ac4b7de1" name="dei:EntityCentralIndexKey" contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67">0001796280</ix:nonNumeric><ix:nonNumeric id="F_a44278fc-02ca-4c0e-8870-25fd385d7fec" name="dei:AmendmentFlag" contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="oric-20240506.xsd"/></ix:references><ix:resources><xbrli:context id="C_cb0f78ff-557b-4726-96e9-e527cc874d67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001796280</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-06</xbrli:startDate><xbrli:endDate>2024-05-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;min-height:0.44in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:6pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dcab8007-a0e7-4bfc-9b54-b9fc97635ef9" contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:6pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">of The Securities Exchange Act of 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_51da80e0-e287-44e1-b788-78391115f18f" contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">May 6, 2024</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:6pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9fc872d6-ab1f-4dfb-8b57-9e119bcda765" contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">ORIC Pharmaceuticals, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:6pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.527%;"/>
    <td style="width:1.68%;"/>
    <td style="width:31.546%;"/>
    <td style="width:1.68%;"/>
    <td style="width:31.566%;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.042in;vertical-align:middle;padding-right:0.042in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:middle;padding-right:0.042in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:middle;padding-right:0.042in;"><p style="font-size:2pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_4c773097-f1d7-4689-b1ae-cb3849e9d351" contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b62fc69d-db40-45e0-ac2f-eab0c34401b6" contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-39269</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_9af79a86-b4f8-4a17-bd82-93760c21788f" contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">47-1787157</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">of incorporation)</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File Number)</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_efb5b063-e31c-44ae-b1f1-c409ea8831a3" contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">240 E. Grand Ave</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b8aaa43e-338c-433d-9b14-89b769d2b6e1" contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">nd</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> Floor</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_517f952a-1179-4075-bc9f-9c5413a8d568" contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">South San Francisco</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2065244-0386-4531-8fbd-dc501657ccb5" contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b3813b7-a78c-4631-8724-32014aeffcf4" contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">94080</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Address of principal executive offices, including zip code)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0e0f9cda-6a84-47be-80bc-763e802ddcc7" contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(650)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_79700f2b-8946-43b0-addb-ef09337d46d5" contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">388-5600</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (Registrant&#8217;s telephone number, including area code)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not Applicable</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Former name or former address, if changed since last report)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:6pt;border-bottom:0.5pt solid;margin-right:40%;text-align:center;"><span style="white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:3pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:0.556%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.46%;"/>
    <td style="width:96.54%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_93081486-5a08-43d0-bc10-cfa1a32ac0e0" contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:5pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:0.556%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.66%;"/>
    <td style="width:96.34%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_f363e08c-c5e6-4b6c-9d71-bdf7507622b6" contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:0.556%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.46%;"/>
    <td style="width:96.54%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_d5968a00-067b-467e-ad32-c6fbdd46eb81" contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:0.556%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:3.46%;"/>
    <td style="width:96.54%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_8cba1aae-120a-45b2-aaf5-1cd1c9899910" contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:37.909%;"/>
    <td style="width:1.137%;"/>
    <td style="width:24.182%;"/>
    <td style="width:0.998%;"/>
    <td style="width:35.774%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:1.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:1.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:1.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:1.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:1.5pt solid;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_cddc22a8-a6f0-48df-87a6-7501b153d9b2" contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1b40d883-badb-4c13-83b2-ea344e0ee25d" contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ORIC</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">The </span><span><ix:nonNumeric id="F_22f843f7-f5b3-40de-b900-2020f249d01f" contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nasdaq</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#160;Global Select Market</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_737541fa-9722-477a-a094-9dd0cce8b97a" contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1c41630-5fb8-43a2-b5b6-43237e2384e8" contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.44in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 6, 2024, ORIC Pharmaceuticals, Inc. issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</span></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="fis_other_events"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span><span id="fis_section_8_other_events"></span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:4.173%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="fis_unidentified_table_2"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.952%;"/>
    <td style="width:1.277%;"/>
    <td style="width:87.772%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="oric-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press Release dated May 6, 2024</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;margin-right:0.009722222222222222in;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:3pt;margin-right:0.009722222222222222in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded with the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.44in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="eolpage3"><span id="fis_signatures"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:4.253%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.18%;"/>
    <td style="width:1.16%;"/>
    <td style="width:4.08%;"/>
    <td style="width:1.16%;"/>
    <td style="width:3.1%;"/>
    <td style="width:1.16%;"/>
    <td style="width:44.16%;"/>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ORIC PHARMACEUTICALS, INC.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="vertical-align:middle;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;&#160;&#160;&#160;Date: May 6, 2024</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Dominic Piscitelli</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Dominic Piscitelli</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.011111111111111112in;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Chief Financial Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Arial;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>oric-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;">
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50%;"></td>
     <td style="width:50%;"></td>
    </tr>
    <tr style="height:12pt;white-space:pre-wrap;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:49.5pt;vertical-align:top;padding-right:0.01in;"><p style="text-indent:-49.5pt;padding-left:49.5pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img48504584_0.jpg" alt="img48504584_0.jpg" style="width:128px;height:36px;">&#160;</p></td>
     <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="font-size:12pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit 99.1</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:Times New Roman;min-width:fit-content;">ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR atypical mutations; updated Phase 1b data expected in the first half of 2025</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Presented initial ORIC-944 Phase 1b monotherapy data demonstrating potential best-in-class profile with strong pharmacokinetic, pharmacodynamic, and safety results in patients with prostate cancer; proceeding into combination with AR inhibitor(s) in metastatic prostate cancer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Presented updated ORIC-944 preclinical data at the 2024 AACR Annual Meeting highlighting superior drug properties and synergistic activity in combination with AR inhibitors in prostate cancer models</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Strengthened cash position with $125 million private placement financing in January 2024; cash and investments of $331.5 million expected to fund operating plan into late 2026</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">SOUTH SAN FRANCISCO and SAN DIEGO, CA &#x2013; May 6, 2024 &#x2013; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today reported financial results and operational updates for the quarter ended March 31, 2024.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;In the first quarter of 2024, we continued making steady progress across our clinical and preclinical programs, while also strengthening our cash position and runway,&#x201d; said Jacob M. Chacko, M.D., president and chief executive officer. &#x201c;Most recently, we announced the selection of provisional recommended phase 2 doses for ORIC-114 that confirm its wide therapeutic index, and we initiated three expansion cohorts in patients with EGFR/HER2 mutated non-small cell lung cancer, including those with active, untreated CNS metastases. For ORIC-944, we presented clinical and preclinical data that further reinforce its promise as a potential best-in-class treatment option for prostate cancer based upon its superior drug properties and clinical half-life versus competitor PRC2 inhibitors. We are laser focused on flawless execution as we continue to advance these two programs towards the initiation of registrational studies, which we anticipate in the second half of 2025.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">First Quarter 2024 and Other Recent Highlights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ORIC-114</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">: a brain penetrant, orally bioavailable, irreversible EGFR/HER2 inhibitor</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Announced the completion of the dose escalation portion of the Phase 1b trial of ORIC-114 and the selection of the provisional recommended phase 2 doses.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Announced first patients dosed across three expansion cohorts in the Phase 1b trial of ORIC-114 in patients with mutated non-small cell lung cancer (NSCLC), including EGFR exon 20 insertion (EGFR exon 20 inhibitor na&iuml;ve), HER2 exon 20 insertion, and EGFR atypical mutations.</font></div></div>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Initiated an extension cohort to evaluate ORIC-114 for the treatment of patients with first-line, treatment-na&iuml;ve EGFR exon 20 insertion NSCLC.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Expect to report updated Phase 1b data in the first half of 2025.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ORIC-944</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">: a potent and selective allosteric inhibitor of PRC2</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Reported initial Phase 1b monotherapy data for ORIC-944 in metastatic prostate cancer supporting advancement into combination development and demonstrating the potential as a best-in-class PRC2 inhibitor, including a clinical half-life of ~20 hours, no signs of CYP autoinduction that was observed with first-generation PRC2 inhibitors, robust target engagement, and a well-tolerated safety profile.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Presented preclinical data at the 2024 AACR Annual Meeting demonstrating superior preclinical drug properties and synergy data in prostate cancer models, reinforcing the promise of ORIC-944 as a potential best-in-class treatment for combination with AR inhibitors. </font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Proceeding with combination of ORIC-944 with AR inhibitor(s) in metastatic prostate cancer and expect to provide a program update in mid-2024.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ORIC-533</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">: a highly potent, orally bioavailable small molecule inhibitor of CD73</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The company is completing a Phase 1b trial and plans to pursue strategic partnership for combination studies.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Discovery Pipeline:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Presented at the 2024 AACR annual meeting the first preclinical data on ORIC-613, a potential first- and best-in-class development candidate selectively inhibiting PLK4.  </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Corporate Highlights:</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Strengthened cash position and runway with a $125 million private placement financing from new and existing healthcare specialist funds in January 2024.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">First Quarter 2024 Financial Results</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cash, Cash Equivalents and Investments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">: Cash, cash equivalents and investments totaled $331.5 million as of March 31, 2024, which the company expects will be sufficient to fund its operating plan into late 2026. </font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">R&amp;D Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">: Research and development (R&amp;D) expenses were $22.0 million for the three months ended March 31, 2024, compared to $19.5 million for the three months ended March 31, 2023, an increase of $2.4 million. The increase was due to a net increase in external expenses related to the advancement of product candidates and discovery programs, as well as higher personnel costs, including additional non-cash stock-based compensation of $0.7 million.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">G&amp;A Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">: General and administrative (G&amp;A) expenses were $7.0 million for the three months ended March 31, 2024, compared to $6.2 million for the three months ended March 31, 2023, an increase of $0.9 million. The increase was primarily due to </font></div></div>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:3.447919145106397%;visibility:hidden;display:inline-flex;justify-content:flex-start;"></font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">higher personnel costs, including additional non-cash stock-based compensation of $0.7 million.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">About ORIC Pharmaceuticals, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients&#x2019; lives by </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Overcoming Resistance In Cancer. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ORIC&#x2019;s clinical stage product candidates include (1) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, (2) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (3) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">www.oricpharma.com</font></font><font style="color:#1d2228;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">and follow us on </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">X</font></font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">or</font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">LinkedIn</font></font><font style="color:#1d2228;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cautionary Note Regarding Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the continued clinical development of ORIC-114 and ORIC-944; ORIC-114, ORIC-944 and ORIC-533 clinical outcomes, which may materially change as patient enrollment continues or more patient data become available; the development plans and timelines for ORIC-114, ORIC-944 and ORIC&#x2019;s other product candidates; the potential advantages of ORIC-114, ORIC-944 and ORIC&#x2019;s other product candidates and programs; plans underlying ORIC&#x2019;s clinical trials and development; anticipated program milestones, including timing of program and data updates and the initiation of registrational studies; the period over which ORIC estimates its existing cash, cash equivalents and investments will be sufficient to fund its current operating plan; and statements by the company&#x2019;s chief executive officer. Words such as &#x201c;believes,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;plans,&#x201d; &#x201c;expects,&#x201d; &#x201c;intends,&#x201d; &#x201c;will,&#x201d; &#x201c;goal,&#x201d; &#x201c;potential&#x201d; and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon ORIC&#x2019;s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company; ORIC&#x2019;s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates; changes in ORIC&#x2019;s plans to develop and commercialize its product candidates; the potential for clinical trials of ORIC&#x2019;s product candidates to differ from preclinical, initial, interim, preliminary or expected results; negative impacts of health emergencies, economic instability or international conflicts on ORIC&#x2019;s operations, including clinical trials; the risk of the occurrence of any event, change or other circumstance that could give rise to the termination of ORIC&#x2019;s license and collaboration agreements; the potential</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">market for ORIC&#x2019;s product candidates, and the progress and success of competing therapeutics currently available or in development; ORIC&#x2019;s ability to raise any additional funding it will need to continue to pursue its business and product development plans; regulatory developments in the United States and foreign countries; ORIC&#x2019;s reliance on third parties, including contract manufacturers and contract research organizations; ORIC&#x2019;s ability to obtain and maintain intellectual property protection for its product candidates; the loss of key scientific or management personnel; competition in the industry in which ORIC operates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section titled &#x201c;Risk Factors&#x201d; in ORIC&#x2019;s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on May 6, 2024, and ORIC&#x2019;s future reports to be filed with the SEC. These forward-looking statements are made as of the date of this press release, and ORIC assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Contact:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Dominic Piscitelli, Chief Financial Officer</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">dominic.piscitelli@oricpharma.com</font></font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">info@oricpharma.com</font></font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ORIC PHARMACEUTICALS, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">CONDENSED BALANCE SHEETS</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share amounts)</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:60.14%;"></td>
    <td style="width:1%;"></td>
    <td style="width:15.88%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1%;"></td>
    <td style="width:18.98%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(unaudited)</font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="7" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash, cash equivalents and short-term investments</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">316,778</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">208,187</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,305</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,410</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">324,083</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">212,597</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Long-term investments</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,694</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">26,852</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Property and equipment, net</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,801</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,862</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,208</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">9,696</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">350,786</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">252,007</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="7" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities and Stockholders' Equity</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,988</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">944</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accrued liabilities</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,222</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,514</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15,210</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20,458</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:35pt;vertical-align:bottom;"><p style="margin-left:35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other long-term liabilities</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,931</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,461</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">22,141</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">27,919</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="text-indent:35pt;vertical-align:bottom;"><p style="margin-left:35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:5pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:5pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders' equity</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">328,645</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">224,088</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:25pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:25pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and stockholders' equity</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">350,786</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">252,007</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ORIC PHARMACEUTICALS, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="statements_operations_comprehensive_lo_1"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">STATEMENTS OF OPERATIONS </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">AND COMPREHENSIVE LOSS</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Unaudited)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share amounts)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.853%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.302000000000001%;"></td>
    <td style="width:1%;"></td>
    <td style="width:4.541%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.302000000000001%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="6" style="vertical-align:bottom;border-bottom:2.25pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended<br>March 31,</font></p></td>
    <td style="vertical-align:bottom;border-bottom:2.25pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</font></p></td>
    <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">21,960</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,516</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,030</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,162</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:20pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:20pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</font></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">28,990</font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">25,678</font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(28,990</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(25,678</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,979</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,733</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</font></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(25,011</font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
    <td style="border-top:0.5pt solid #000000;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(23,945</font></p></td>
    <td style="border-top:0.5pt solid #ffffff03;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other comprehensive (loss) income:</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#160;Unrealized (loss) gain on investments</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(420</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">792</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(25,431</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(23,153</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(0.37</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(0.53</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
    <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares outstanding, basic and diluted</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">67,349,551</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">45,090,166</font></p></td>
    <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img48504584_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img48504584_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (T!] # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ]7BGP?_ .1MNO\ KQ?_ -&1U[77!B%:9]%EK;H7?=A1116)WA1110 4444
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MYMC=P7*>L3AL?7'2OEVI(+B>UF6:WFDAE7H\;%6'XBL98:+V9W4\VJ+XU?\
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M'KJM&ZT:W78****@W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M***S]2UJQTI,W,PWXR(UY8_A_C45*D*<>:;LBH0E-\L5=FA5#4-9L-,'^DSJ
MKXR(UY8_A7%ZGXPOKS=':_Z+$>ZG+G\>WX5SK,S,68DL>22>M>!BL_A'W<.K
M^;V^[_ACU\/E,GK6=O)'5:CXWN9<I81"!?[[_,WY=!^M<U<W5Q>2^9<3/*_J
M[9J&BOGL1C*^(=ZLK_E]Q[%'#4J*]R-@HHHKF-PHHHH **** "BBB@ HHHH
M**** /0/ W_($F_Z^6_]!6NFKF? W_($F_Z^6_\ 05KIJ^^RS_=*?H?)8[_>
M)^H5D^(_^00W^^M:U9/B/_D$-_OK1F?^YU?\+,\+_&CZG&T445^8GTP4444
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MDH.+LSV:5:%6/-!W"BBBI-0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4?6O(/['_O\ X?\ !/E.BOJRBCZUY!_8_P#?_#_@GRG17U911]:\@_L?^_\
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M"UOC?92SD=Y9V_H0*["BLW5F^IU1P>'CM!?F8<'@WPW;@;-$LCC_ )Z1!_\
MT+-7X]&TN$8BTVS0?[,"C^E7:*AR;ZFRIP6R1&D$,;;DB13ZA0*DHHI%B,JL
MI5@"#U!%0/8VD@P]K P'9HP:L44":3W,V7P[HD^?-T>P?.>6MD)_E6?/X#\+
MW&=^C6XS_P \RR?^@D5T5%4I26S(=&G+>*^XXBY^%/AF?/EI=V^?^>4V<?\
M?0-8EW\&H2";+6)%]%FA#9_$$?RKU*BJ5::ZF,L#AY;Q_0\-O?A/XCMLFW^R
MW8[".7:?_'@!^M<SJ'AS6M+R;W3+J%1U<QDK_P!]#C]:^F**U6)DMSEGE-)_
M"VCY3HKZ4U+PIH6KY-[I=L[GK(J['_[Z7!KC-4^#UC*&?2[^6W;M'.-Z_3(P
M1^M:QQ,7OH<-3*ZT?AU/'J*ZC5_A]XCT<,[V)N81_P M;4^8/R^\/Q%<P002
M",$=0:W4E+8X)TYTW::L)1113("BBB@ HHHH **** "BBB@ JS8:A=Z7>)=V
M-P\$Z?==#S]/<>QJM10";3NCV[P?\2K36?+L=5*6M^?E5^D<Q]O[I]C^'I7?
M5\IUZ)X,^)<^E^7I^M.\]D/E2?J\0]_[R_J/TKDJX?K ]K"9E]BM]_\ F>T4
M5%;7,%Y;1W-M*DL,@W(Z'(85+7(>TG?5#9(HYHFBE19(V&&5AD$>A%<;J?PN
M\.:A(TD44UDY.3]G?"_]\D$#\,5VE%5&4H[,SJ4:=16FKGG,7P=T=9"9=1OG
M3/"KL4X^N#75:)X1T3P^=]A9*LV,&:0[W_,]/PQ6Y13E4G+1LBGA:--WC%7"
MBBBH-PHHHH **** "BBB@ HHHH **** "BBN.U_XBZ3H.L0Z<RO<,'Q<O&>(
M!_4],C^O%5&+D[(SJ584US3=D=C145O<0W=M'<6\JRPR*&1T.0P/>I:DT3N%
M<=XG\,;M]_8)\W66)1U_VA_A78T5S8O"4\53]G4_X8WP^(G0GSP/&:*[7Q/X
M8W;[^P3YNLL2CK_M#_"N*KX7%X2IA:G)/Y/N?58?$0KPYHA1117,;A1110 4
M444 %%2V]M/=3"*WB>60]%49-=1IW@B:3#ZA-Y2_\\X^6_$]!^M=.'P=?$.U
M*-_R^\PK8FE15YNQR8!8@ $D\ "MFQ\+:I>X;R?(C/\ %-\OZ=:[ZPT>PTU?
M]%MT5N[GEC^)J]7OX?A^*UKROY+_ #/(K9NWI2C]YRUEX(LXL-=S23M_=7Y%
M_P ?UK?M=-LK$ 6UK%&?55Y_/K5JBO:H8+#T/X<$OS^\\RKB:U7XY-A11174
M8!1110 4444 %%%% !1110 4444 %%%% !1110!#/:6]R,30I)[LO/YUE7/A
MFUDR8'>$^GWA_C^M;=%<F(P.&Q'\6"?Y_?N:TZ]2G\+L<7=:!?6V2L8F0=X^
M3^76LP@J2&!!'4&O1ZK75A:WBXGA5CV;H1^->!BN&8/7#RMY/;[_ /AST*69
MM:5%]QP%%=#>>&'7+6<NX?W'X/YUA36\UM)LFC:-O1ABOF<5@,1A7:K&WGT^
M\]*EB*=5>XR.BBBN,V"BBB@ HHHH ***Z/1=#.5NKQ..J1G^9_PKLP6"JXRJ
MJ=->KZ(RK5HT8\T@T31-VV[NUXZQQGO[FNEHHK]$P6"I8.E[.G\WW/G:]>5:
M7-(***1W6-&=V"JHR23@ 5V&(M%9.F^(K'4[R6VA8AU/R;N/,'J/\*UJSI5J
M=6/-3=T74ISIOEFK,****T("BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $95=2K*&4C!!&
M0:YC5_A]X<U?<S6(M9C_ ,M;7]V?R^Z?RKJ**:DX[$3IPJ*TU<\5USX3:K8A
MI=+F2_B'/EGY)!^'0_G^%<%<VT]G</!<PR0S(<-'(I5A]0:^IZS-9\/Z7K]O
MY.HVB2X&%?&'3Z-U%=$,2U\1YE?*H2UI.S_ ^9J*[[Q1\,-0T@/=:67OK,9)
M0#][&/<#[WU'Y5P-=<9J2NCQ:M&=*7+-6"BBBJ,PHHHH **** "KNDZK=Z+J
M<.H64FR:)LC/1AW!]0:I44-7&FXNZ/ICP]KMKXBT>'4+4X#C#QDY,;CJI_ST
MP:U*^?\ P#XJ;PWK:I.Y_L^Z(2<'HA[/^'?VS[5]  @@$'(/0BO.JT^27D?4
M8/$JO3N]UN%%%%9'6%%%% !1110 4444 %%%% !1110 4444 %%%% !7SGXY
M_P"1VU;_ *[G^0KZ,KYS\<_\CMJW_7<_R%=.&^)GE9M_"CZG/T445VG@!111
M0 4444 >@_!__D;;K_KQ?_T9'7M=>*?!_P#Y&VZ_Z\7_ /1D=>UUP8CXSZ3+
M/]W^;"BBBL#T HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "J6K:M9Z)ITM]?2B.",?BQ[ #N33=9UFRT'39+^_EV1)T ^\Y
M[*H[DU\_^*?%-[XHU$W%P2ENAQ#;@_+&/ZGU-;4J3F_(XL9C(X>-EK)EGQ=X
MRO?%-YAB8;"-OW-N#_X\WJW\NWOS-%%=\8J*LCYJI4E4DY2=V%%%%,D****
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M_B7^H_KURK4>;WH[G9@<=[/]W4^'\O\ @'O5%16]Q#=VT=Q;RK+#(H9'0Y#
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*XCQA\.[/7UDO+ ):ZEU)QA)3_M#L??\\UV]%5&3B[HSJTH58\LU='RY?V%U
MIE[)9WL#PW$9PR,.1_\ 6JM7T1XN\(6?BJPVL%BO8Q^XN,<C_9;U7^5> ZEI
MUUI.H36-[$8IXFVLI_F/4&N^E54UYGS6+PDL/+NGU*M%%%:G(%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<%:MSZ+8^BP6!5%<\_B_(****P/1"BBB@ HHHH **** "BBB@ HHHH ****
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M?E7H-?>Y=C%BJ"GU6C]3Y+&8=T*KCTZ!1117<<H4444 %%%% !1110 4444
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M=5117F2DY.[/JZ=.-.*A'9!1112+"BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB/2NXK@KU.:5ELCZ3+L-[*GS/=A1116!Z 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\V>+7$
MGC#6"!C%Y*/R8C^E8U7M9G^TZYJ%QG/FW,CY^K$U1KU8[(^-J.\V_,****9(
M4444 %=Y\) 3XQDP.EH^?^^EK@Z]$^#T1/B6^EYPMF5_-U/]*SK? SIP2OB(
M>I[11117FGU84444 %%%% !1110 4444 %%%% !1110 5\Y^.?\ D=M6_P"N
MY_D*^C*^<_'/_([:M_UW/\A73AOB9Y6;?PH^IS]%%%=IX 4444 %%%% 'H/P
M?_Y&VZ_Z\7_]&1U[77BGP?\ ^1MNO^O%_P#T9'7M=<&(^,^DRS_=_FPHHHK
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNO\ KQ?_ -&1U[77BGP?_P"1MNO^O%__ $9'7M=<&(^,^DRS_=_FPHHHK ]
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAH3\D?'8J')6E'S"BBBNHP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNEKSJTN:;9]3@J/LJ*3WW"BBBLCK"BBB@ HHHH **** "BBB@ HHHH ****
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M](KG? ME]@\$Z7$1AGA\T_\  R6_K715YE5WFV?682')0C'R"BBBH.@****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0HHHK,Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^<_'/_ ".VK?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\O:J2
M=8O23DFXDR3_ +QKZAKY>U3_ )"U[_UW?_T(UU87=GC9O\,/F5****[#Q HH
MHH **** "O>?A:FSP/;G.=\LA^GS8_I7@U>^?##_ )$2S_ZZ2_\ H9KGQ/P'
MI95_'?I_D=A1117"?1!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !7SOX^@^S^.=53&,RA_P#OI0W]:^B*\*^*]OY/C5I/^>]O')_-
M?_9:Z,,_?/,S6-Z*?9G$4445W'SP4444 %%%% !7K/P9N,Q:O;$]&BD ^NX'
M^0KR:N_^$=WY/BN>W)XN+5@!_M @_P LUE65X,Z\!+EQ$6>VT445YQ]2%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KR3XRVNVZTJ[ ^^DD1/T((_]"->MUP?Q:LOM'A%+
MA5YMKE7)]%(*_P RM:T7::./'PYL/)'A]%%%>B?+A1110 4444 %;W@J^_L[
MQEI5P3A3.(V/L_RG_P!"K!IR.T<BNA*LI!!'8TFKJQ4)<DE)=#ZJHJGI5\NI
MZ19WR?=N(5DQZ9&<5<KRGH?8IIJZ"BBB@84444 %%%% !1110 4444 %%%%
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MS_R.VK?]=S_(5]&5\Y^.?^1VU;_KN?Y"NG#?$SRLV_A1]3GZ***[3P HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !61XJL/[3\*ZG: ;F>W8H/5@-R_J!6O133L[DRB
MI1<7U/E.BM/Q'IQTGQ'J%CMVK#.P0?[!.5_0BLRO53NKGQTHN+<7T"BBB@04
M444 %%%% 'N7PIU07OA/[(S9DLI63'?:WS _F6'X5W5>&_"K5_L'BHV;MB*^
MC,?MO'*_^S#\:]RKSZ\>6;/I\OJ^TH+RT"BBBL3M"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% 'B_P 7M+^S>(+745&$NX=K'_;3C^17\J\[KWOXFZ3_ &GX
M.GE1<RV;"X7'H.&_0D_A7@E>A0E>'H?,YC2Y*[??4****V.$**** "BBB@":
MTNI;*\ANH&VRPNLB'T(.17TUI6H1:MI5KJ$'^KN(PX&>F1R/J#Q^%?+]>N_"
M'7?-L[G1)G^>$^= "?X3]X#Z'!_X$:Y\3"\>;L>GE=;DJ.F]G^9Z?1117"?0
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!0UK4X]&T6\U&7!6WC+@'^(]A^)P/QKYFGGDN;B6XF8M+*Y
M=V/<DY)KU3XO:[B.UT.%^6_?SX].BC^9_ 5Y/7=AX6C?N?/9I6YZO(ME^844
M45T'F!1110 4444 %=[\)M+^V>*9+YES'90E@?\ ;;Y1^F[\JX*O=/A9I!T_
MPF+IUQ+?2&7WV#A1^A/XUC7ERP9VY?2]I77EJ=Q1117GGTX4444 %%%% !11
M10 4444 %%%% !7E_P 9O^//2/\ KI+_ "6O4*\O^,W_ !YZ1_UTE_DM:T/X
MB./,/]VE\OS/(Z***]$^7"BBB@ HHHH EM?^/R'_ *Z+_.OJ>OEBU_X_(?\
MKHO\Z^IZY,5T/;R?:?R_4****Y#V0HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** &NB2QM'(H9&!5E89!![&O O'GA%_#.K>9 I.G7))A;^X>Z'Z=
MO;\:]_K/UO1K77M)GT^[7,<@X;'*-V8>XK6E4Y'Y')C,*L13MU6Q\QT5?UK1
M[K0M5GT^\7$L1X8='7LP]C5"O13OJCY>47%V>X4444""BBB@ I02""#@CH12
M44 >[?#OQ@/$&F_8;R3_ (F-LHW$]94Z!OKV/Y]Z[:OE[3-2NM(U*"_LY-D\
M+;E/8^H/L>E?17AOQ!:^)-&BO[;Y2?EECSDQN.H/]/8UPUZ7*[K8^BR_%^UC
MR3^)?B:]%%%<YZ04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %?.?CG_D=M6_Z[G^0KZ,KYS\<_\ ([:M_P!=
MS_(5TX;XF>5FW\*/J<_1117:> %%%% !1110!Z#\'_\ D;;K_KQ?_P!&1U[7
M7BGP?_Y&VZ_Z\7_]&1U[77!B/C/I,L_W?YL****P/0"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#R;XQZ9B;3M55>&5K>0_3YE_FWY5Y97T/X^TK^UO!
MM_$JYEA7[1']4Y/YC(_&OGBN_#RO"W8^;S.ER5^;N%%%%;GGA1110 4444 %
M>^?#36/[5\(01.V9K(FW?)YP.5_#:0/P->!UW7PLUO\ LWQ/]AD;$%^OE^PD
M'*G^8_&L:\>:!VY?6]G75]GH>Y4445YY].%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 ,FB2>&2&50T<BE64]P1@BOF76],DT;6[S3I,[H)2H)[KV/
MXC!_&OIVO(_B_HOEW5IK42_+*/(F(_O#E3^(R/\ @(KHPT[2MW/,S2CSTN==
M/R/+Z***[CYX**** "BBB@ K2T#5Y="URTU*+),+@LH/WEZ,/Q&:S:*&KJS'
M&3BU);H^IK2ZAOK.&ZMW#PS('1AW!&14U>8?";Q+YUM)H%R_SQ9DMB3U7^)?
MP//XGTKT^O,G#DE8^LP]95J:F@HHHJ#<**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ JO?WL&FV$][<MMA@0R.?8#^=6
M*\J^+7B4;8_#]M)SQ+=8/XJA_P#0ORJZ<.>5C#$UU1IN;/-M8U2?6=7NM1N#
M^\G<MC/W1V'T P/PJC117II6T/DVW)W84444""BBB@ HHHH MZ7I\NJZK:V$
M/^LN)5C!QTR>3] .:^G+6VBL[2&U@7;%"BQHOH ,"O(OA%HGVC4[G695_=VR
M^5$3_?8<G\%_]"KV*N+$SO+E['T&54>6FZCZ_D%%%%<QZ@4444 %%%% !111
M0 4444 %%%% !7E_QF_X\](_ZZ2_R6O4*\O^,W_'GI'_ %TE_DM:T/XB./,/
M]VE\OS/(Z***]$^7"BBB@ HHHH EM?\ C\A_ZZ+_ #KZGKY8M?\ C\A_ZZ+_
M #KZGKDQ70]O)]I_+]0HHHKD/9"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** .1\>^$5\3:5YMNH&HVP)A;IO'=#]>WO]37@3HT;LCJ5=3A
ME88(/H:^JZ\G^*/@_:6\0V$?!/\ I<:CH>TG]#^!]:ZL/5M[K/(S+"<R]M#=
M;GE=%%%=AX04444 %%%% !71^#/%,WA?65F)9K*;"7,8[K_>'N/\1WKG**4D
MI*S*ISE3DI1W1]46]Q#=VT=Q!(LD,JAT=3PP/(-25X[\,/&/V*X70;^3_1IF
M_P!&=C_JW/\ #]#V]_K7L5>;4@X2LSZK#8B->GSKYA1114'0%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?.?CG_D
M=M6_Z[G^0KZ,KYS\<_\ ([:M_P!=S_(5TX;XF>5FW\*/J<_1117:> %%%% !
M1110!Z#\'_\ D;;K_KQ?_P!&1U[77BGP?_Y&VZ_Z\7_]&1U[77!B/C/I,L_W
M?YL****P/0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!" P((!!X(-?-
M7B;23H?B2^T_&$BE)C]T/*_H17TM7E/Q@T;FRUJ)/^G>8C\U/_H0_*NC#RM*
MW<\W-*//1YUNCRFBBBNX^="BBB@ HHHH *?#-);SQS1.4DC8.C#J"#D&F44
M?3'AS6(]>T"TU%, RI\ZC^%QPP_,&M2O&_A-XB%GJ4NBW#XANOGAR>!(!R/Q
M'_H(]:]DKS:L.25CZO"5_;4E+KU"BBBLSI"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*** "BBB@ HHHH **** "BBB@ HHHH *^<_'/_([:M_UW/\ (5]&5\Y^.?\
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MN"WN9,6%X0DF3PC?PO\ T/L?:L:]/FC=;H[\OQ/L:EI;,]ZHHHKSSZ4****
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7F'Q/\
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M_P#'Y#_UT7^=?4]?+%K_ ,?D/_71?YU]3UR8KH>WD^T_E^H4445R'LA1110
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MS19YC?N/IZ'TKAKTN5\RV/H<NQ?M(^SENOQ1LT445SGIA1110 4444 %%%%
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M EM?^/R'_KHO\Z^IZ^6+7_C\A_ZZ+_.OJ>N3%=#V\GVG\OU"BBBN0]D****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!LL231/
M%*BO&ZE65AD,#U!KY]\<>$Y/#&KD1!FL+@EK=SV]4/N/U%?0E9FOZ':^(=(F
MT^Z'RN,HX',;=F%:TJG)+R./&855X66ZV/F:BKVKZ5=:)JD^GWB;9HFQ[,.Q
M'L15&O13OJ?,-.+LPHHHH$%%%% !1110![G\.O&/]OZ=_9][)G4K9>I/,R=
MWU'0_@>]=S7R[INHW.DZC!?6<ACGA;<K?T/L1P:^B_#7B"V\2Z-%?V^%8_+-
M%GF-^X_P]JX:]+E?,MCZ++\7[6/LY_$OQ->BBBN<](**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "OG/QS_R.VK?]=S_(5]&5\Y^.
M?^1VU;_KN?Y"NG#?$SRLV_A1]3GZ***[3P HHHH **** /0?@_\ \C;=?]>+
M_P#HR.O:Z\4^#_\ R-MU_P!>+_\ HR.O:ZX,1\9])EG^[_-A1116!Z 4444
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M;OW]*RO!WC>\\+7 B?=/ITC9D@SRI_O+Z'VZ']:Z%AY<M^IYLLSI*KR=.Y]
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[?NW/^RW;Z']:[>N.47%V9[U*K"K'F@[A1114F@4444 %%%% !1110 4444
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MG7U/7RQ:_P#'Y#_UT7^=?4]<F*Z'MY/M/Y?J%%%%<A[(4444 %%%% !1110
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M8XKG[-<G_EA<85B?8]#^!S[5QSHRB>Y0QU&MHG9]F=/11161V!1110 4444
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M,O"/]KU'O^?OPU=T9*2NCYRK2G2ERS5F%%%%49A1110 4444 %%%% !1110
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M0Y=B_:Q]G/XE^)L4445SGIA1110 4444 %%%% !1110 4444 %%%% !1110
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M_!;?*WXMU_+%<?16\:,(]#SJV/KU=&[+R%9F=BS,68G)).2:2BBM3C"BBB@
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M:M_UW/\ (5]&5\Y^.?\ D=M6_P"NY_D*Z<-\3/*S;^%'U.?HHHKM/ "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH XCQ-\--*UHO<6.+"]/)*+^[<^Z]OJ/UKR/7?"VK^')MFH6K+&3A9T^:
M-OHW]#@U])TR:&*XA:&>))8G&&1U#*P]P:WIUY1T>J//Q&74JNL=&?*U%>T^
M(?A1IU_OGT>3[#.>?*;+1,?YK^&1[5Y=K?A?6/#\F-0LG2//$R_-&?\ @0_D
M>:ZX58SV/$KX.K1^):=S'HHHK0Y@HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !16EI&@:KKLWEZ=92SX.&<#"+]6/ KTWP_\([: K/KMQ]H<<_9X"53\
M6ZG\,5$ZD8;G10PE6M\"T[]#S#2=#U+7;K[/IUI)._\ $0,*ON2>!7JWAKX4
MV5CLN=:<7DXY\A>(E/OW;]![&N_L[*UT^V6VL[>."%>B1J% _*IZY)XB4M%H
M>UA\MIT]9ZO\!L<:11K'&BHBC"JHP /0"G445SGI!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI_+]0HHHKD/9"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK18F75')/*:;^&31\IT5]07.D:;>$FZT^TGSU\V%6_F*R9_ GA>X^_HUN/\
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MHHH **** "BBB@ HHHH *C:W@9BS0QDGJ2HJ2B@"+[+;_P#/"+_O@4?9;?\
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M).BVF3Z+C^55]:CV,WE%3I)'SE17T/\ \*^\*_\ 0'B_[^/_ (T?\*^\*_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
6*** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>oric-20240506.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-05-06T13:07:09.7787+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.oricpharma.com/20240506" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:oric="http://www.oricpharma.com/20240506" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="oric-20240506.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationsAbstract" xlink:label="us-gaap_HealthCareOrganizationsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_HealthCareOrganizationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Health Care Organizations [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationsAbstract" xlink:to="us-gaap_HealthCareOrganizationsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140058799953232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001796280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  06,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ORIC Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-1787157<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">240 E. Grand Ave<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">2nd Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">388-5600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ORIC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=>Y!L/?P&HT=S8\?M_P!4$L#!!0    ( $2!IE@D'INBK0   /@!   :
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=
M6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\
MI%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X
M\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].
MM.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " !$@:9899!YDAD!  #/ P
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M<' N>&UL4$L! A0#%     @ 1(&F6&9\S;[N    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 1(&F6)E<G",0
M!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " !$@:982NE*&(D$  #4$0  &               @($-"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 1(&F6)^@&_"Q
M @  X@P   T              ( !S P  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M    " !$@:98EXJ[',     3 @  "P              @ &H#P  7W)E;',O
M+G)E;'-02P$"% ,4    " !$@:98'#AEZC\!   \ @  #P
M@ &1$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 1(&F6"0>FZ*M
M^ $  !H              ( !_1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ 1(&F6&60>9(9 0  SP,  !,              ( !
MXA(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  +!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="oric-20240506.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="oric-20240506.htm">oric-20240506.htm</File>
    <File>oric-20240506.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "oric-20240506.htm": {
   "nsprefix": "oric",
   "nsuri": "http://www.oricpharma.com/20240506",
   "dts": {
    "inline": {
     "local": [
      "oric-20240506.htm"
     ]
    },
    "schema": {
     "local": [
      "oric-20240506.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_cb0f78ff-557b-4726-96e9-e527cc874d67",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oric-20240506.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cb0f78ff-557b-4726-96e9-e527cc874d67",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "oric-20240506.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.oricpharma.com/20240506/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-24-053551-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-053551-xbrl.zip
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MHI?0H6)! 5_WY:"MVA9Y]5-R+E+]\X9'D>0?=CY_"ZV(QU[ L.N%##N1;>+
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M%^&#@R09(5VFE8VBC+.XGZ>RZ%1+<;WTO1$QA6O]%!K$1+LWAXU,4N2=B@1
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MT51BP$,>B58R=$BSHK'U!& &8?KXH52R(UT9C9KI .E=<)N3WJ8?6(>GO?D
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M_!YPG@_<:7,%ZC=0<LPC/Y0K=0;/</'*()1#9(^!"Q/S8 # $P2)23.S_^+
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M^@@Q)@C1BU-Y>CUKZ*2OJTX@MI+I:V,ZPBU;X$/2\0DUG;=MY=J69J-B>$X
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MF)0JHOZ.<VW:[2!V,9'?[>9& 15%5;.Z@S,,]$?VWB?=3W[ABI-$F1][(@S
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M7])=Q^3<]R+G?K".&P9Y191![&4:S<H Y?C%%HA'8CLU:LD[ K2G,K8_"38
M>S..T9-&FL2^"XU.R.E%"*!2<NEMQ(_TMJ5( TQ?:.B3?[5 <B(9]7PGQN"^
MRO ZK6W&\6@A.HY=#B[>*/]MUM_U-Y_,/+F.>BR@'(@(ME7$]T,0DIY<""IV
MTG7434B&#IV+GL(1..L0U#J@&#_NP@?P-L/$>*9?A6FU9Q#VN"__G;[O<B'=
M4@OKXXM))*$Y,@,N)IIB_<X1;/U"<"M*/&CDA&6&T0WT7F,"11&:EP"X-6[S
MDQY'XPJ%5O;>"!P[(2)V5P(/A%[%EO,RM.'!Y_22PJS,ENDE$*?B2QQDLG("
M-OK=&8BYBNQJG$.8<IMQFWI!BK!R?*31FD<)'[B+O)+LA1&Z!12^5=W)4/DM
M&KU/L"%!J#)@/@,_DO,XP/.ZLQ;N_B>8&RN7"O]@V.,IAPMSH0IJQ9N&*]H
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MGH\4&>#W[SJ!,_KPE_?O^I'G?OA_4$L! A0#%     @ 1(&F6$:CD]$#%0
M8M,  !$              ( !     &]R:6,M,C R-# U,#8N:'1M4$L! A0#
M%     @ 1(&F6*W&QG8""@  \7\  !$              ( !,A4  &]R:6,M
M,C R-# U,#8N>'-D4$L! A0#%     @ 1(&F6"$@PHJ@'P  1<(!  \
M         ( !8Q\  &]R:6,M97@Y.5\Q+FAT;5!+!08      P # +L    P
%/P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>oric-20240506_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="oric-20240506.xsd" xlink:type="simple"/>
    <context id="C_cb0f78ff-557b-4726-96e9-e527cc874d67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001796280</identifier>
        </entity>
        <period>
            <startDate>2024-05-06</startDate>
            <endDate>2024-05-06</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67"
      id="F_92bdf68c-569c-4b31-86c2-b683ac4b7de1">0001796280</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67"
      id="F_a44278fc-02ca-4c0e-8870-25fd385d7fec">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67"
      id="F_dcab8007-a0e7-4bfc-9b54-b9fc97635ef9">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67"
      id="F_51da80e0-e287-44e1-b788-78391115f18f">2024-05-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67"
      id="F_9fc872d6-ab1f-4dfb-8b57-9e119bcda765">ORIC Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67"
      id="F_4c773097-f1d7-4689-b1ae-cb3849e9d351">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67"
      id="F_b62fc69d-db40-45e0-ac2f-eab0c34401b6">001-39269</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67"
      id="F_9af79a86-b4f8-4a17-bd82-93760c21788f">47-1787157</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67"
      id="F_efb5b063-e31c-44ae-b1f1-c409ea8831a3">240 E. Grand Ave</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67"
      id="F_b8aaa43e-338c-433d-9b14-89b769d2b6e1">2nd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67"
      id="F_517f952a-1179-4075-bc9f-9c5413a8d568">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67"
      id="F_d2065244-0386-4531-8fbd-dc501657ccb5">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67"
      id="F_4b3813b7-a78c-4631-8724-32014aeffcf4">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67"
      id="F_0e0f9cda-6a84-47be-80bc-763e802ddcc7">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67"
      id="F_79700f2b-8946-43b0-addb-ef09337d46d5">388-5600</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67"
      id="F_93081486-5a08-43d0-bc10-cfa1a32ac0e0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67"
      id="F_f363e08c-c5e6-4b6c-9d71-bdf7507622b6">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67"
      id="F_d5968a00-067b-467e-ad32-c6fbdd46eb81">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67"
      id="F_8cba1aae-120a-45b2-aaf5-1cd1c9899910">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67"
      id="F_cddc22a8-a6f0-48df-87a6-7501b153d9b2">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67"
      id="F_1b40d883-badb-4c13-83b2-ea344e0ee25d">ORIC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67"
      id="F_22f843f7-f5b3-40de-b900-2020f249d01f">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67"
      id="F_737541fa-9722-477a-a094-9dd0cce8b97a">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_cb0f78ff-557b-4726-96e9-e527cc874d67"
      id="F_a1c41630-5fb8-43a2-b5b6-43237e2384e8">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
